Close Menu

NEW YORK (GenomeWeb) – Barclays has initiated coverage of Genomic Health, Quidel, and Cepheid while it upgraded Hologic's stock to Equal Weight.

In a research note, analyst Jack Meehan rated Genomic Health Underweight with a price target of $25 per share. "[O]pportunities for profitability are further out," he said, noting that he prefers other companies offering "more robust and better validated tests" for prostate cancer prognosis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.